Benchmarking of real-time, field-deployable whole-genome sequencing of Plasmodium falciparum using Nanopore technology Open Access
July 29, 2026
Malaria parasite genomes have been generated predominantly using Illumina short-read sequencing that requires expensive equipment, is time-consuming with complex protocols,…
High-dose, short-course primaquine after point-of-care G6PD testing for the radical cure of Plasmodium vivax malaria: a safety study in Papua New Guinea and Indonesia
June 29, 2026
Background High total dose primaquine (PQ 7 mg/kg) over 7 days can improve treatment adherence and reduce Plasmodium vivax malaria recurrences. We…
Risk perceptions of high-dose primaquine and tafenoquine among Plasmodium vivax malaria stakeholders in Ethiopia: a qualitative study
June 29, 2026
Background: Adherence to radical cure for Plasmodium vivax remains a major challenge for malaria control programmes. Novel regimens, such as 7-day high-dose primaquine…
Efficacy of Metofluthrin Spatial Emanators to Reduce Human Vector Contact in Papua New Guinea
June 25, 2026
Background Alternative vector control tools are needed to address rising malaria burden in Papua New Guinea (PNG), where outdoor transmission…
Latent cytomegalovirus disrupts innate NK cell responses to P. falciparum and impairs parasite control in first infection in adults
June 23, 2026
NK cells are innate and adaptive responders to malaria, with functional responses underpinned by NK cell heterogeneity. One driver of…
Pfcrt copy number amplification detected in a Plasmodium falciparum outbreak
June 19, 2026
Antimalarial resistance is one of the greatest threats to malaria elimination. Following an outbreak of Plasmodium falciparum infection in Sabah Malaysia in…
Understanding community and health system acceptability, readiness and perspectives on the introduction of new vector control approaches for malaria control in Papua New Guinea
June 16, 2026
Background Malaria remains a major public health challenge in Papua New Guinea (PNG) and accounted for most malaria cases and…
The pyrrolidinamide antimalarial drug MMV367 rapidly clears blood-stage Plasmodium falciparum in healthy adults with experimental malaria
June 10, 2026
Fast-acting antimalarial drugs are needed to address the emergence of artemisinin resistance in the protozoan parasite Plasmodium falciparum, the major cause of…
Analysis of the effect of primaquine dose on efficacy, safety, and tolerability in patients with Plasmodium vivax malaria in Ethiopia: a systematic review and individual patient data meta-analysis
June 6, 2026
Background The 8-aminoquinoline antimalarials are used to prevent P. vivax relapses. Recent evidence suggests high total dose primaquine (7 mg/kg) provides optimal efficacy,…
Dissemination of EFFORT trial results in Indonesia: a stakeholder meeting report on tafenoquine and primaquine for radical cure of Plasmodium vivax
May 27, 2026
The EFFORT clinical trial was conducted in four countries (Cambodia, Ethiopia, Indonesia, and Pakistan) to evaluate the safety and effectiveness…